These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The future of positron emission tomography in oncology depends on interactive basic, nuclear and clinical research. Buell U; Cremerius U; Zimny M Eur J Nucl Med; 1997 Oct; 24(10):1330. PubMed ID: 9432468 [No Abstract] [Full Text] [Related]
4. [Whole body positron emission tomography (PET) with (18F)-fluorodeoxyglucose]. Grupo PET de la SEMN Rev Esp Med Nucl; 2002 Apr; 21(2):128-30. PubMed ID: 11879625 [No Abstract] [Full Text] [Related]
5. An alternative method to normalize clinical FDG studies. Sandell A; Ohlsson T; Erlandsson K; Strand SE J Nucl Med; 1998 Mar; 39(3):552-5. PubMed ID: 9529310 [TBL] [Abstract][Full Text] [Related]
7. [Recommendations for the use of PET-CT with 18F-FDG in radiotherapy planning]. García Vicente AM Rev Esp Med Nucl Imagen Mol; 2012; 31(6):364. PubMed ID: 23063325 [No Abstract] [Full Text] [Related]
8. Is there a future for clinical fluorine-18 radiopharmaceuticals (excluding FDG)? Stöcklin GL Eur J Nucl Med; 1998 Dec; 25(12):1612-6. PubMed ID: 9917190 [TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography: background, possibilities and perspectives in neuroscience. Paans AM Acta Neurol Belg; 1997 Sep; 97(3):150-3. PubMed ID: 9345585 [TBL] [Abstract][Full Text] [Related]
11. Testing which is the fitter position sensor for a cyclotron liquid target. da Costa OL Appl Radiat Isot; 2014 Jan; 83 Pt A():37-40. PubMed ID: 24231305 [TBL] [Abstract][Full Text] [Related]
12. On FDG PET metabolic imaging to assess myocardial viability. Brunken RC; Go RT; MacIntyre WJ J Nucl Med; 2000 Apr; 41(4):25N. PubMed ID: 10768553 [No Abstract] [Full Text] [Related]
13. False-positive FDG PET in patients with pancreatic masses: an issue of proper patient selection? Zimny M; Buell U; Diederichs CG; Reske SN Eur J Nucl Med; 1998 Sep; 25(9):1352. PubMed ID: 9841214 [No Abstract] [Full Text] [Related]
14. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. Schelbert HR; Hoh CK; Royal HD; Brown M; Dahlbom MN; Dehdashti F; Wahl RL J Nucl Med; 1998 Jul; 39(7):1302-5. PubMed ID: 9669415 [No Abstract] [Full Text] [Related]
15. The incremental value of diagnostic tests. Wagner HN J Nucl Med; 1997 Feb; 38(2):241-2. PubMed ID: 9025745 [No Abstract] [Full Text] [Related]
16. [PET technology applied for FDG based examination--in consideration of the approval by the health insurance system-Part 2]. Amano M Nihon Hoshasen Gijutsu Gakkai Zasshi; 2003 Mar; 59(3):398-9. PubMed ID: 12740562 [No Abstract] [Full Text] [Related]
17. Spinal metastases of a high grade astrocytoma visualized with FDG-PET. Woesler B; Kuwert T; Probst-Cousin S; Schäfers M; Wassmann H; Gullotta F; Schober O Clin Nucl Med; 1997 Dec; 22(12):863-4. PubMed ID: 9408658 [No Abstract] [Full Text] [Related]
18. New 18F-radiopharmaceuticals. Stöcklin G Nuklearmedizin; 1990 Mar; 29(2):80. PubMed ID: 2339087 [No Abstract] [Full Text] [Related]
19. Isotopic labeling with short-lived radionuclides represents the future for clinical PET imaging. For the proposition. Harkness B Med Phys; 2002 Dec; 29(12):2897-8. PubMed ID: 12512725 [No Abstract] [Full Text] [Related]